APA (7th ed.) Citation

RS, F., HS, R., J, C., S, L., G, F., E, G., . . . DJ, S. (2025). A Decade After Approval of the First CDK4/6 Inhibitor: A Look Back at Palbociclib's Journey from Discovery to Approval and What's Next in CDK Inhibition in Breast Cancer. Targeted oncology, 20(6), 917. https://doi.org/10.1007/s11523-025-01175-z

Chicago Style (17th ed.) Citation

RS, Finn, et al. "A Decade After Approval of the First CDK4/6 Inhibitor: A Look Back at Palbociclib's Journey from Discovery to Approval and What's Next in CDK Inhibition in Breast Cancer." Targeted Oncology 20, no. 6 (2025): 917. https://doi.org/10.1007/s11523-025-01175-z.

MLA (9th ed.) Citation

RS, Finn, et al. "A Decade After Approval of the First CDK4/6 Inhibitor: A Look Back at Palbociclib's Journey from Discovery to Approval and What's Next in CDK Inhibition in Breast Cancer." Targeted Oncology, vol. 20, no. 6, 2025, p. 917, https://doi.org/10.1007/s11523-025-01175-z.